Boyer M, Sendur MAN, Rodriguez-Abreu D, Park K, et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. J Clin Oncol 2021 Jan 29:JCO2003579. doi: 10.1200/JCO.20.03579.
PMID: 33513313